Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 19/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17009984 | 1.00 | IDH1 (0.44) | IDH1ALDH1A1HTT | |
| SCHEMBL17009981 | 1.00 | IDH1 (0.44) | IDH1ALDH1A1HTT | |
| SCHEMBL28635139 | 0.90 | IDH1 (0.42) | IDH1ALDH1A1HTT | |
| SCHEMBL17019136 | 0.90 | IDH1 (0.42) | IDH1ALDH1A1HTT | |
| SCHEMBL17019135 | 0.90 | IDH1 (0.42) | IDH1ALDH1A1HTT | |
| SCHEMBL17009671 | 0.89 | IDH1 (0.45) | IDH1 | |
| SCHEMBL17009672 | 0.89 | IDH1 (0.45) | IDH1 | |
| SCHEMBL17009669 | 0.89 | IDH1 (0.45) | IDH1 | |
| SCHEMBL17009725 | 0.82 | IDH1 (0.44) | IDH1ALDH1A1HTT | |
| SCHEMBL17009722 | 0.82 | IDH1 (0.44) | IDH1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3319945-B1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3319945-B1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2021-04-28 | — | — | EP | disclosed |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-15 | — | — | US | disclosed |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-15 | — | — | US | disclosed |
| EP-3105209-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3105209-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-10179123-B2 | 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-15 | — | — | US | disclosed |
| US-10179123-B2 | 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-15 | — | — | US | disclosed |
| US-20180207137-A1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207137-A1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | US | disclosed |
| US-9957235-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-01 | — | — | US | disclosed |
| US-9957235-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-01 | — | — | US | disclosed |
| US-9957235-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-01 | — | — | US | disclosed |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| WO-2017005674-A1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-12 | — | — | WO | disclosed |
| EP-3105209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207137-A1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | HRH1, MDN1, NAT1 | IDH1 44/4885ALDH1A1 154/4885HTT 1560/4885 |
| US-10179123-B2 | 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors | HRH1, MDN1, NAT1 | IDH1 44/4885ALDH1A1 154/4885HTT 1560/4885 |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | HRH1, HRH2, HRH3 | IDH1 173/4885ALDH1A1 741/4885HTT 1369/4885 |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | HRH1, HRH2, HRH3 | IDH1 173/4885ALDH1A1 741/4885HTT 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.